OMass Therapeutics discovers and develops small-molecule medicines for patients with rare and immunological diseases by studying drug targets in their native molecular surroundings with mass spectrometry.

Founders

• Professor Dame Carol Robinson
• Jonathan Hopper · Vice President, Platforms and Founder
  He completed a PhD in native mass spectrometry under Professor Neil Oldham and then moved to Oxford to develop native-mass-spectrometry approaches for membrane proteins with Professor Dame Carol Robinson.